- Home
- RWAY vs PBYI Comparison
RWAY vs PBYI Comparison
Compare RWAY & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RWAY | PBYI |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.2M | 263.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | RWAY | PBYI |
|---|---|---|
| Price | $6.85 | $6.10 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.86 | N/A |
| AVG Volume (30 Days) | ★ 470.2K | 432.9K |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 19.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $6.75 | N/A |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | ★ $5.70 | $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.61 | $2.58 |
| 52 Week High | $11.41 | $7.68 |
Technical Indicators
Market Signals| Indicator | RWAY | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 45.55 |
| Support Level | N/A | $5.85 |
| Resistance Level | $9.53 | $6.15 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 15.61 | 28.27 |
Price Performance
Historical ComparisonAbout RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.